carbamates has been researched along with nimodipine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adler, G; Berger, FM; Calabrese, P; Frölich, L; Gertz, HJ; Hampel, H; Haupt, M; Jendroska, K; Kohler, J; Mielke, R; Paulus, HJ; Pilartz, H; Riepe, MW; Zedlick, D | 1 |
| Antonello, RM; Bava, A; Cazzato, G; Griggio, S; Moretti, R; Torre, P; Ukmar, M | 1 |
| Gauthier, KM; Hammock, BD; Hillard, CJ; Ho, WS; Huang, H; Thompson, J; Wheelock, CE | 1 |
| Kaba, H; Takahashi, Y | 1 |
1 trial(s) available for carbamates and nimodipine
| Article | Year |
|---|---|
Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.
Topics: Aged; Aged, 80 and over; Aspirin; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Drug Therapy, Combination; Female; Humans; Male; Nimodipine; Phenylcarbamates; Psychotic Disorders; Rivastigmine; Treatment Outcome; Vasodilator Agents | 2004 |
3 other study(ies) available for carbamates and nimodipine
| Article | Year |
|---|---|
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihydroergotoxine; Donepezil; Family Practice; Female; Follow-Up Studies; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Neuroprotective Agents; Nimodipine; Nootropic Agents; Phenylcarbamates; Piperidines; Piracetam; Psychiatric Status Rating Scales; Risk Factors; Rivastigmine; Time Factors; Vasodilator Agents | 2002 |
Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Amidohydrolases; Aniline Compounds; Animals; Arachidonic Acid; Arachidonic Acids; Benzamides; Benzoxazines; Carbamates; Dose-Response Relationship, Drug; Drug Synergism; Endocannabinoids; Enzyme Inhibitors; Glycerides; In Vitro Techniques; Male; Middle Cerebral Artery; Morpholines; Naphthalenes; Nimodipine; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Thromboxanes; Vasoconstriction; Vasoconstrictor Agents | 2007 |
Muscarinic receptor type 1 (M1) stimulation, probably through KCNQ/Kv7 channel closure, increases spontaneous GABA release at the dendrodendritic synapse in the mouse accessory olfactory bulb.
Topics: Alkaloids; Animals; Anticonvulsants; Calcium; Calcium Channel Blockers; Calcium Channels, R-Type; Carbachol; Carbamates; Cholinergic Agonists; Dendrites; Diclofenac; Excitatory Amino Acid Antagonists; Furans; GABA Antagonists; gamma-Aminobutyric Acid; In Vitro Techniques; Ion Channel Gating; KCNQ Potassium Channels; Mice; Mice, Inbred BALB C; Muscarinic Antagonists; Naphthalenes; Nimodipine; Olfactory Bulb; Patch-Clamp Techniques; Phenylenediamines; Piperidines; Pirenzepine; Potassium Channel Blockers; Receptor, Muscarinic M1; Receptors, Glutamate; Synapses | 2010 |